Pellucid marginal degeneration (PMD) is an eye condition that has been around for a long time, but is still relatively unknown and poorly understood. PMD is a progressive, non-inflammatory condition that causes thinning of the cornea at the outer edge, or margin, of the eye. This can lead to decreased vision, light sensitivity, and other vision-related problems. The exact cause of PMD is unknown, but it is thought to be related to genetics, environmental factors, or a combination of both. In this article, we will explore the mysteries of PMD, discuss the symptoms, diagnosis, and treatment options, and provide an overview of the current research.
Pellucid marginal degeneration (PMD) is a progressive, non-inflammatory eye disease that affects the peripheral cornea. It is characterized by thinning of the cornea at the outer edge, or margin, of the eye. This thinning can cause decreased vision, light sensitivity, and other vision-related problems. PMD is most commonly seen in people between the ages of 20 and 40, although it can occur at any age.
The most common symptom of PMD is decreased vision in the affected eye. This can range from mild to severe, depending on the severity of the condition. Other symptoms may include light sensitivity, glare, halos around lights, double vision, and astigmatism. In some cases, the condition may also cause pain or discomfort.
PMD is typically diagnosed during a comprehensive eye exam. During the exam, the doctor will look for signs of thinning of the cornea at the outer edge of the eye. They may also use a slit lamp to examine the cornea more closely. Imaging tests, such as OCT (optical coherence tomography) or ultrasound, may also be used to confirm the diagnosis.
Treatment of PMD is aimed at relieving symptoms and preserving vision. In most cases, this can be done with glasses, contact lenses, or surgery. In severe cases, corneal transplantation may be necessary.
Currently, there is limited research on PMD, and the exact cause of the condition is unknown. However, researchers believe that genetics, environmental factors, or a combination of both may play a role. Studies have also suggested that PMD may be associated with certain autoimmune diseases, such as rheumatoid arthritis.
Pellucid marginal degeneration is a progressive, non-inflammatory eye condition that can cause decreased vision, light sensitivity, and other vision-related problems. Although the exact cause of PMD is unknown, it is thought to be related to genetics, environmental factors, or a combination of both. Treatment of PMD is aimed at relieving symptoms and preserving vision, and can include glasses, contact lenses, or surgery. Research on PMD is ongoing, and further studies are needed to better understand the condition and develop more effective treatments.
1.
Stem Cell Selection Unneeded for SSc Transplant Therapy?
2.
Lung Transplant for Lung Cancer: Promising, in Rare Cases
3.
Rural-urban disparities seen in cervical cancer
4.
Obesity linked to subsequent neoplasms in childhood cancer survivors
5.
New policy review highlights the importance of health-related quality of life in advanced cancer
1.
Empowering Oncology with Data: Cloud Security, Real-World Evidence, and Clinical Insights
2.
Transplant Oncology and Anti-Cancer Immunosuppressants: The Evolution of a Paradigm in Cancer Care
3.
Is AI The New Radiologist For Breast MRI?
4.
Pediatric Oncology at the Cutting Edge: From Early Diagnosis to Lifesaving Therapies
5.
Bone Marrow Regeneration in Hematologic Recovery
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part VI
2.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
4.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation